6h agoWSJ BusinessNEUTRAL 50General
Health Care Roundup: Market Talk
Find insight on HaItian International, Telix Pharmaceuticals and more in the latest Market Talks covering Health Care.
Archived explainer. For the current picture see today's TLX page.
Why Is TELIX PHARMACEUTICAL ADR (TLX) Stock Down Today?
By the Top Tier Newswire AI Desk · September 21, 2026 at 9:33 AM ET · reviewed against 8 wire stories
TELIX PHARMACEUTICAL ADR (TLX) is down -10.96% in the latest session. Our newswire has captured 8 stories on TLX across 6 sources in the last 36 hours, with AI sentiment reading mixed (avg 51/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
TLX stock fell 10.96% to $11.21 on Friday, marking a significant decline driven by the announcement of a $1.65 billion acquisition of Germany’s ITM Isotope. The stock opened with an 8.8% gap down from the prior close and continued to trade lower throughout the session, reaching a session low of $11.20. The deal, which expands Telix’s radiopharmaceutical capabilities, has sparked immediate market skepticism.
What Happened
Telix Pharmaceuticals announced its intention to acquire ITM Isotope, a German isotope manufacturer, in a transaction valued at $1.65 billion. The deal includes 105.8 million shares issued to ITM sellers, giving them a 23.7% stake in the combined company post-closing. The acquisition is part of Telix’s long-term strategy to become a vertically integrated radiopharmaceutical company. However, the stock reacted negatively, with the price falling below the previous session’s close and reaching a 52-week low. The transaction was also highlighted in a slide deck published by the company on September 21, 2026, in conjunction with a market call.
The market appears to be pricing in concerns over the valuation of the deal and the dilutive effect of the share issuance. The stock’s decline aligns with broader pre-market trends, where Telix was among the stocks gapping down ahead of the U.S.-China summit.
What The Data Shows
The stock opened at $11.48, a -8.8% gap down from $12.59, and traded in a narrow range between $11.20 and $11.48. Volume was 0.1 million shares, or 0.3 times the 3-month average. The stock has moved from $12.34 to $12.59 over the last 8 sessions before today’s decline. Telix has a market cap of $4.3 billion, a P/E ratio of 132.0, and a beta of 0.60. Recent insider activity includes a $20,000 purchase by CFO Darren Charlton on September 7.
What To Watch
Telix has no scheduled earnings report in the near term. Investors will likely monitor coverage breadth and analyst reactions to the ITM acquisition, as well as how the market digests the deal’s strategic and financial implications.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
TLX by the numbers
Last: $11.21Session: -10.96%7 sessions: -7.23%Coverage: 8 stories / 6 sourcesAI sentiment: 51/100 (mixed)Mkt cap: $4.3BP/E: 132.052w: $6.28 to $13.11
The headlines behind the move
7h agoSeeking AlphaBEARISH 32General
At a glance: stocks gapping down premarket
Stock market premarket update: TLX and NVO lead gap-down movers as futures rise ahead of the U.S.-China summit.
12h agoSeeking AlphaNEUTRAL 50General
Telix Pharmaceuticals Limited (TLX) Telix Pharmaceuticals Limited, - M&A Call - Slideshow
2026-09-21. The following slide deck was published by Telix Pharmaceuticals Limited in conjunction with this event.
14h agoSeeking AlphaBULLISH 63M&A
Telix to buy Germany’s ITM Isotope for $1.65B to expand radiopharma footprint
Telix Pharmaceuticals to buy Germany’s ITM Isotope in a $1.65B deal, boosting radiopharma scale and 2026 revenue outlook—read the details now.
15h agoInvesting.com MarketsBEARISH 42General
Why is Telix Pharmaceuticals stock sliding today?
Why is Telix Pharmaceuticals stock sliding today?
17h agoGlobeNewswireBULLISH 73M&A
Telix and ITM Join Forces to Create a Radiopharmaceutical Powerhouse
Transformational merger reinforces Telix’s long-term growth strategy as a vertically integrated radiopharmaceutical company with enhanced capabilities...
18h agoTechStock²BEARISH 34General
Telix’s US$1.65 Billion ITM Deal Adds 105.8 Million Shares as Stock Falls 3%
Sydney, September 21, 2026, 10:42 (AEST) Telix traded at A$17.31, down 3.03%, shortly after the ASX opened. ITM sellers would receive 105.8 million shares and own 23.7% after closing. The acquisition adds isotope manufacturing and US$273 million of 2025 revenue. Telix Pharmaceuticals Limited (ASX:TLX; NASDAQ:TLX) fell 3.03% to A$17.31 in Sydney. The move followed its…
19h agoBloombergBULLISH 67M&A
Telix to Buy Isotope Maker ITM in Deal Worth Up to $2.35 Billion
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →
More on TLX: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier TLX move explainers: 2026-09-21 · 2026-09-16 · 2026-09-15 · 2026-09-14 · 2026-09-02 · 2026-08-21